The Manufacturers Life Insurance Company Makes New Investment in Pharvaris N.V. $PHVS

The Manufacturers Life Insurance Company bought a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS) during the 2nd quarter, Holdings Channel reports. The firm bought 23,646 shares of the company’s stock, valued at approximately $818,000.

A number of other institutional investors have also recently made changes to their positions in PHVS. Seven Fleet Capital Management LP raised its holdings in shares of Pharvaris by 472.3% during the first quarter. Seven Fleet Capital Management LP now owns 316,697 shares of the company’s stock valued at $8,947,000 after purchasing an additional 261,355 shares during the last quarter. PSP Research LLC purchased a new stake in Pharvaris in the fourth quarter worth approximately $569,000. BlackRock Inc. bought a new stake in Pharvaris in the 2nd quarter worth approximately $26,677,000. DV Trading LLC bought a new stake in Pharvaris in the 1st quarter worth approximately $4,067,000. Finally, Deutsche Bank AG purchased a new stake in Pharvaris during the 2nd quarter valued at $1,849,000.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Morgan Stanley increased their price target on Pharvaris from $41.00 to $46.00 and gave the company an “overweight” rating in a report on Thursday, June 25th. Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Thursday, August 13th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. UBS Group set a $74.00 target price on Pharvaris in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada raised their target price on Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.08.

Insider Buying and Selling

In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $34.77, for a total value of $79,692.84. Following the completion of the sale, the chief executive officer owned 130,625 shares in the company, valued at $4,541,831.25. This represents a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total value of $1,089,968.88. Following the completion of the sale, the director owned 315,167 shares of the company’s stock, valued at approximately $11,185,276.83. The trade was a 8.88% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 118,655 shares of company stock valued at $4,188,002. 11.84% of the stock is owned by company insiders.

Pharvaris Trading Down 1.1%

PHVS opened at $35.25 on Friday. Pharvaris N.V. has a 1-year low of $20.65 and a 1-year high of $38.13. The company has a market capitalization of $2.31 billion, a PE ratio of -11.56 and a beta of -2.33. The firm’s 50 day simple moving average is $34.78 and its two-hundred day simple moving average is $31.03.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Equities analysts forecast that Pharvaris N.V. will post -3.15 earnings per share for the current fiscal year.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.